B. Braun Avitum AG and CytoSorbents Corporation Announce Global Co-Marketing Agreement to Promote the OMNI® Continuous Blood Purification Platform with CytoSorb®

Joint marketing of CytoSorb® with B. Braun’s newest OMNI® blood purification platform will offer greater access of this advanced treatment of deadly inflammation to critically ill patients.

Digital Diabetes Management Market Size, Trends & Forecast

In this image released on Tuesday, March 2, 2021, the CytoSorb® adsorber is used in critical care for the extracorporeal removal of cytokines and inflammatory mediators from the bloodstream. B. Braun Avitum

B. Braun Avitum AG and CytoSorbents Corporation Announce Global Co-Marketing Agreement to Promote the OMNI® Continuous Blood Purification Platform with CytoSorb®

B. Braun Avitum AG and CytoSorbents Corporation Announce Global Co-Marketing Agreement

新闻详情页-B. Braun Group

Apheresis Machines Market 2021: Comprehensive Study Explores

Apheresis Machines Market 2021: Comprehensive Study Explores

Apheresis Machines Market 2021: Comprehensive Study Explores

B. Braun Avitum AG and CytoSorbents Corporation Announce Global Co-Marketing Agreement to Promote the OMNI® Continuous Blood Purification Platform with CytoSorb® - Cytosorbents